TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39589666
Drug: Generic nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Generic nab-paclitaxel monotherapy
Study: 39589666
Drug: Generic nab-paclitaxel-based
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Generic nab-paclitaxel-based combination therapy
Study: 39589666
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ≥ 4 treatment cycles
Study: 39589690
Drug: Tarlatamab (0.003,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mg) administered every 2 weeks (Q2W) with a step dose regimen starting at 3 mg; infused over 1 hour.
Study: 39589721
Drug: Nurse-delivered brief
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-delivered brief behavioral treatment for insomnia (BBTI)
Study: 39589730
Drug: Immunosuppressive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapies
Study: 39590165
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and Dexamethasone (Len/Dex) followed by Donor Lymphocyte Infusions (DLIs)
Study: 39591190
Drug: Prime-2-CoV_Beta vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prime-2-CoV_Beta vaccine
Study: 39591365
Drug: Autologous adipose-derived
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose-derived regenerative cells (ADRCs) (4.20×10^7 ± 1.75×10^7 cells) and 30-cc lipotransfer
Study: 39591420
Drug: Medication Coordinator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Coordinator intervention with medication review and suggested amendments documented in electronic discharge letter sent to GP
Study: 39591420
Drug: Medication Coordinator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Coordinator intervention
Study: 39591551
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg once daily plus Pembrolizumab 200 mg once every 3 weeks
Study: 39591551
Drug: Chemotherapy (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Paclitaxel 175 mg/m2)
Study: 39592468
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (including L. rhamnosus DSM 32550, Humiome® L. plantarum DSM 34532, B. lactis DSM 32269, B. longum DSM 32946, fructooligosaccharides and zinc)
Study: 39592547
Drug: FIL200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL200 (200 mg once daily)
Study: 39592547
Drug: FIL100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL100 (100 mg once daily)
Study: 39592547
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg biweekly)
Study: 39592626
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy (AIT)
Study: 39592888
Drug: BAT4406F (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT4406F (escalated doses ranging from 20 to 750 mg)
Study: 39593101
Drug: Robotics-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotics-assisted therapy (RAT) at home for 30 consecutive days after 2 therapist-supervised clinic onboarding sessions.
Study: 39593537
Drug: Cervical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical therapy protocol + active cervical postural treatment for 4 weeks
Study: 39593537
Drug: Active cervical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cervical postural treatment for 4 weeks
Study: 39593541
Drug: Reformer Pilates
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reformer Pilates exercise (6-week program, 45 min/twice per week)
Study: 39594812
Drug: Roflumilast in
Normalized name: Product containing roflumilast in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast in combination with R-CHOP (Ro+R-CHOP)
Study: 39596792
Drug: Inhaled Colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Colistin via nebulizer type A
Study: 39596792
Drug: Inhaled Colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Colistin via nebulizer type B
Study: 39599585
Drug: Calcifediol 75
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol 75 µg
Study: 39599585
Drug: Calcifediol 100
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol 100 µg
Study: 39599686
Drug: Carnosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine supplementation (2 g/day for 14 weeks)
Study: 39599746
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (ω3) supplementation (300 mg capsules, 2 daily for 9 weeks)
Study: 39599746
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (VitD) supplementation (50,000 IU tablet, 1 weekly for 9 weeks)
Study: 39599964
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional swallowing therapy without videos)
Study: 39601122
Drug: Pulsed Field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Field Ablation (PFA) as first-line therapy
Study: 39601122
Drug: Pulsed Field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Field Ablation (PFA) after prior class I/III AAD therapy
Study: 39601214
Drug: Electrical shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical shock treatment (5 milliamps)
Study: 39601265
Drug: Clesrovimab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clesrovimab (100 mg for full-term, 20, 50, 75, or 100 mg for preterm)
Study: 39601271
Drug: Center M
Normalized name: clean air center MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Center M intervention (4 one-hour weekly group telehealth sessions)
Study: 39601296
Drug: Sub-ulcer foam
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-ulcer foam sclerotherapy and compression therapy
Study: 39601296
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy only
Study: 39601743
Drug: Clopidogrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel monotherapy for normal, rapid, or ultrarapid CYP2C19 metabolizers (n=69)
Study: 39601743
Drug: Prasugrel or
Normalized name: prasugrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel or ticagrelor monotherapy for loss-of-function allele carriers (n=29)
Study: 39601743
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel and aspirin) for all patients initially
Study: 39601933
Drug: PharmaCAP intervention
Normalized name: Pharmasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PharmaCAP intervention (clinical pharmacist-led medication review, pain assessment, education, and counseling)
Study: 39601981
Drug: 2 h/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h/12 h intravenous infusion of Cyclosporin A (CsA)
Study: 39601981
Drug: 22 h
Normalized name: C18-22 Hydroxyalkyl Hydroxypropyl Guar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 h continuous infusion of Cyclosporin A (CsA)
Study: 39602139
Drug: Nemolizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (30 mg or 60 mg depending on baseline weight) administered every 4 weeks for 24 weeks
Study: 39602341
Drug: CAR T-cell
Normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T-cell therapy (ARI0002h; academic BCMA-targeted CAR T-cell therapy)
Study: 39602441
Drug: Peer-assisted telemedicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-assisted telemedicine HCV treatment (TeleHCV)
Study: 39602479
Drug: MIC spray
Normalized name: Ophthalmic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC spray mixed with 6 mg aspirin + placebo tablet (Treatment 1)
Study: 39602479
Drug: MIC spray
Normalized name: Ophthalmic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC spray mixed with 6 mg wintergreen oil + placebo tablet (Treatment 2)
Study: 39602479
Drug: MIC spray
Normalized name: Ophthalmic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC spray mixed with 6 mg wintergreen oil + 325 mg aspirin tablet (Treatment 3)
Study: 39602624
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF)
Study: 39602624
Drug: Subcutaneous lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenacapavir
Study: 39602629
Drug: 1 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 primary dose and 1 booster dose of PCV10 (1p+1)
Study: 39602629
Drug: 2 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 primary doses and 1 booster dose of PCV10 (2p+1)
Study: 39602629
Drug: 3 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 primary doses of PCV10 (3p+0)
Study: 39602629
Drug: 0 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 primary doses and 1 booster dose of PCV10 (0p+1)
Study: 39603709
Drug: ivarmacitinib 4
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 4 mg
Study: 39603709
Drug: ivarmacitinib 8
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 8 mg
Study: 39603709
Drug: ivarmacitinib 4
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 4 mg and 8 mg
Study: 39603779
Drug: Abbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated antiplatelet therapy (APT) for 1 month
Study: 39603779
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy (APT) for ≥3 months
Study: 39604382
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery training along with traditional physical therapy program
Study: 39604779
Drug: Oral betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betamethasone (BTM) at 0.3 mg/kg/day for 3 days, 0.15 mg/kg/day for 2 days, and 0.05 mg/kg/day on the last day
Study: 39604779
Drug: Oral betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betamethasone (BTM)
Study: 39604957
Drug: Vinorelbine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine at a dose of 25 mg/m2
Study: 39605008
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g resistant potato starch (RPS)
Study: 39605008
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g resistant potato starch (RPS)
Study: 39605014
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Arm C)
Study: 39605077
Drug: 800 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 ml total bacterial count fecal microbiota transplantation
Study: 39605077
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml total bacterial count fecal microbiota transplantation
Study: 39605293
Drug: Resistance Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Exercise Combined with Cognitive Intervention Therapy
Study: 39605874
Drug: Elamipretide 40
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide 40 mg daily subcutaneous administration for 48 weeks followed by a 4-week follow-up period.
Study: 39606219
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX regimen chemotherapy (S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2) combined with tislelizumab and low-dose radiation therapy (LDRT)
Study: 39606707
Drug: Biopsychosocial rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsychosocial rehabilitation therapy (personalized program based on one of three rehabilitation treatment modules: graded activity, exposure)
Study: 39606837
Drug: Galinpepimut-S (WT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galinpepimut-S (WT1 peptide vaccine)
Study: 39607652
Drug: Radiation exposure
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation exposure treatment
Study: 39607729
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m)
Study: 39608001
Drug: Sleep Treatment
Normalized name: Sleep
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sleep Treatment Education Program (STEP-1)
Study: 39608608
Drug: Low-AF maize
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-AF maize and groundnut flours provided monthly to the intervention group.
Study: 39608608
Drug: Skin lotion
Normalized name: Silicone Skin Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin lotion distributed monthly to the control group.
Study: 39608975
Drug: Sintilimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (3 mg/kg for body weight <60 kg; 200 mg for ≥60 kg) every 3 weeks until 24 months or 35 cycles and 3 doses of the HPV quadrivalent vaccine (initial dose prior to sintilimab initiation, with subsequent doses at 2 and 6 months)
Study: 39608989
Drug: Intralesional rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intralesional rituximab injection
Study: 39608989
Drug: Involved site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved site radiation therapy (ISRT)
Study: 39609094
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg weekly) + standard of care (SOC)
Study: 39609094
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg weekly) continued
Study: 39609094
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg weekly) in non-dermatomyositis (DM) group
Study: 39609094
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg weekly) in DM group
Study: 39609274
Drug: Low-dose (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (0.05 mCi/kg) group
Study: 39609274
Drug: High-dose (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (0.1 mCi/kg) group
Study: 39609822
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg with piperaquine 640 mg
Study: 39609822
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg with piperaquine 960 mg
Study: 39609822
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg with piperaquine 1440 mg
Study: 39610761
Drug: ACQUIRE Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACQUIRE Therapy
Study: 39610995
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (3 weekly supervised sessions: 35 min moderate-intensity treadmill walking + 25 min strength exercises, starting at gestational weeks 12-18)
Study: 39611098
Drug: Sequential extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential extracorporeal blood purification (EBP) therapies; specific hemofilter prescription, dose, and anticoagulation strategies not detailed.
Study: 39611098
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment based on clinical and molecular data; details on dosage and duration not specified.
Study: 39611098
Drug: Dynamic CRRT
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic CRRT prescription; details on dosage and duration not specified.
Study: 39611771
Drug: secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 300 mg every 2/4 weeks (SECQ2W/SECQ4W)
Study: 39612802
Drug: Pn-MAPS24v (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pn-MAPS24v (1 μg, 2 μg, or 5 μg per PS)
Study: 39612919
Drug: Nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (125 mg/m2 weekly) with trastuzumab and pertuzumab
Study: 39612921
Drug: Low-dose ChAdOx1.tHIVconsv1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ChAdOx1.tHIVconsv1 (C1)
Study: 39612921
Drug: Full-dose ChAdOx1.tHIVconsv1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose ChAdOx1.tHIVconsv1 (C1) boosted by MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4)
Study: 39612921
Drug: Vaccine-elicited T-cell
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-elicited T-cell frequencies
Study: 39612928
Drug: Control (rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy)
Study: 39613097
Drug: Dupilumab (100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (100/200 mg by body weight) every 2 weeks for 52 weeks
Study: 39613100
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin therapy in monotherapy
Study: 39613100
Drug: LLT combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLT combination therapy
Study: 39613100
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering therapy (LLT)
Study: 39613120
Drug: Maribavir 400
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 400 mg twice daily (n=142)
Study: 39613120
Drug: Investigator-assigned therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-assigned therapy (IAT) (n=69)
Study: 39613428
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg verapamil administered orally once daily
Study: 39613437
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 ATA for 90 minutes
Study: 39613437
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for VOCs (including hydration, analgesics, normobaric oxygen therapy, and when medically indicated, antibiotic therapy and/or transfusions)
Study: 39614356
Drug: Daily average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily average concentrations of PM
Study: 39614356
Drug: Daily average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily average concentrations of nitrogen dioxide (NO2)
Study: 39614707
Drug: Sildenafil (phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (phosphodiesterase inhibitor)
Study: 39614857
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Glasses (VR-G) - patients watched a 360-degree video with nature sounds before surgery
Study: 39614865
Drug: Compression tights
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression tights ON (AM-ON) during medications
Study: 39614865
Drug: Compression tights
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression tights OFF (AM-OFF) during medications
Study: 39614986
Drug: Biphasic cartilage-repair
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic cartilage-repair implant (BiCRI)
Study: 39615342
Drug: COVIVAC 3
Normalized name: COVID-19 LAV Non-US Vaccine (COVIVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVIVAC 3 μg
Study: 39615342
Drug: COVIVAC 6
Normalized name: COVID-19 LAV Non-US Vaccine (COVIVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVIVAC 6 μg
Study: 39615398
Drug: 12-month intervention
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month intervention integrating a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression
Study: 39615618
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT; acetyl-salicylic-acid 100mg plus clopidogrel 75mg daily)
Study: 39615889
Drug: 1 weekly
Normalized name: granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 weekly IA injection of 5 mL PRP for 3 weeks
Study: 39616365
Drug: FallFitness exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: FallFitness exercise program (multicomponent exercise program delivered weekly for 8 weeks)
Study: 39616603
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of HepB-CpG vaccine (n=174)